EyeGate ekes out a tiny IPO to fund its R&D efforts

Massachusetts' EyeGate Pharmaceuticals ($EYEG) picked up $10 million in an IPO do-over, raising cash to support its sole clinical candidate. The company priced 1.2 million shares at $8.50 each, making its way to the Nasdaq after scrapping previous IPO plans last year. With the funds, EyeGate will advance EGP-437, a treatment for a range of inflammatory ocular diseases that relies on the company's proprietary delivery device. Earlier this month, Valeant Pharmaceuticals ($VRX) bought into the program, trading $1 million up front and promising as much as $32.5 million more tied to regulatory and sales milestones. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.